Abstract Submission

PRESENTATION MODALITY – ORAL and E-POSTER

Rules:

1. Only original UNPUBLISHED breast cancer-related papers will be accepted.

2. Each paper should choose the subdivision in which it fits, whether Basic Research and Translational Research, Tracking, Epidemiology, Imaging, Locoregional treatment (includes rehabilitation) and Systemic treatment.

3. Abstract formatting:

– Use spacing 1 with font 10 (Times New Roman). Leave 1.5 cm margins on both sides and justify the text.

– Maximum number of words: 300 (not including title, authors, institution and keywords).

– Do not use paragraphs. If abbreviations and acronyms are used, these are to be explained the first time they appear in the text. Do not start sentences with numerals.

– Do not use tables or diagrams. These may be displayed on the day of the oral presentation or in the poster text.

– Text division should be in the following order: title, authors, institution, objectives, methodology, results, conclusion, keywords. This structure is not necessary for case reports.

4. Authors:

– A maximum of eight authors (one author and seven coauthors) per paper is admitted.

– The author submitting the abstract should be registered for the event and have paid it integrally.

– The presenting author should also be registered for the event and have paid it integrally.

– The authors should be cited by full name, separating the authors’ names by commas. (NAMES WITH ABBREVIATIONS WILL NOT BE ACCEPTED) E.g.: Antônio Batista Silva, Fábio Gomes Santos.

– Service where the work was carried out, without using abbreviations and informing the city, state and country.

– Submission of abstracts EXCLUSIVELY in ENGLISH.

– ATTENTION: The keywords should be in compliance with the DeCs  (https://decs2020.bvsalud.org/cgi-bin/wxis1660.exe/decsserver/?IsisScript=../cgi-bin/decsserver/decsserver.xis&interface_language=p&previous_page=homepage&previous_task=NULL&task=start).

5. Papers should be submitted through the website bbcs.org.br.

6. Deadline for submissions: March 30, 2025.

7. The Judging Committee will select only papers relevant to the scientific community.

8. All papers will be reviewed by the Scientific Committee, which will approve or not their presentation. Due to physical limitations for presentations, the Committee also reserves the right to reschedule certain papers from one session to another, depending on availability of time and space.

9. The authors of selected papers will be notified in advance by e-mail.

10. The best papers will be selected for oral presentation, according to the judgment of the Evaluation Committee. The other papers will be presented as Fast Presentation
    and posters, during the specific session.

Sole paragraph: The presenting authors of the 15 best papers will be awarded with air ticket and accommodation if Brazilians or accommodation if from other countries. The fist author (presenting author) for the Fast Presentation will be awarded with accommodations for two nights.

11. For General Session the author will have 10 (ten) minutes of oral presentation, followed by 3 (three) minutes of debate with questions from the discussants and audience.

12. For Fast Presentation session the author will have 4 (four) minutes of oral presentation, followed by 2 (two) minutes of debate with questions from the discussants and audience.

13. The approved papers presentation material should be exclusively in English; however, the presentation may be delivered in Portuguese.

14. In the case of a poster, will be in printed format and the dimensions will be forwarded to the author.

15. Papers that do not follow the instructions will be automatically excluded.

16. If the paper submitted is rejected, the registration fee will not be refunded, except for those who requested a refund on the date informed on the online registration tab.

17. The presenting author of the best paper will be awarded with air ticket, accommodation and registration to the San Antonio 2025 in Texas / USA.

18. The presenting author of the best paper in Locoregional Treatment will be awarded with R$ 5,000.00 (five thousand reais) to be paid when the event ends.

19. The best paper in Epidemiology will be awarded, as well.  The presenting author will be awarded with air ticket, accommodation and registration for the Jornada Paulista de Mastologia – JPM 2025.

20. The best paper in Imaging will be awarded, as well.  The presenting author will be awarded with registration for the Jornada Paulista de Mastologia – JPM 2025.

21. Another award is the Unicentro BR, aimed at the best research work carried out in Brazil, with the author being 45 years old or younger on the date of the paper submission (born from 1980 onwards). The best paper in this category be awarded with R$ 5,000.00 (five thousand reais) to be paid to the presenting author when the event ends.

22. The best paper in Systemic Treatment will be awarded with R$ 5,000.00 (five thousand reais) to be paid out when the event ends (paid to the presenting author).

23. The best paper in Tracking will be awarded with R$ 2,000.00 (two thousand reais) to be paid out when the event ends (paid to the presenting author).

24. The best paper in Basic Research and Translational Research be awarded with R$ 2,000.00 (two thousand reais) to be paid when the event ends (paid to the presenting author).

25. Awards are not cumulative.

26. All approved abstracts will be published in a supplement of the Mastology journal, which is why strict compliance with editorial rules is required (including keywords according to DeCS descriptors).

27. Evaluation criteria:

A. Study Methods

A1. Systematic review of randomized studies with meta-analysis, registration in PROSPERO and PRISMA/PICOTS methodology.

A1. Randomized experimental studies with registration in ReBEC/ClinicalTrials.gov and CONSORT methodology.

A2. Systematic review of randomized studies, with meta-analysis.

A2. Molecular – Studies in “omics” (genomics, transcriptomics, proteomics).

A2. Randomized experimental studies.

A3. Systematic review of randomized studies, without meta-analysis.

A3. Systematic review of non-randomized studies, with meta-analysis.

A3. Molecular, functional (in vitro/in vivo).

A3. Non-randomized experimental studies.

A4. Systematic review of non-randomized studies, without meta-analysis.

A4. Molecular – Biomarkers identification (with validation methodology).

A4. Prospective cohort and case-control studies with sample calculation.

A5. Ecological, cross-sectional, and retrospective cohort studies.

A5. Studies using clinical or molecular databases.

A5. Prospective cohort and case-control studies without sample calculation.

A6. Integrative or non-systematic review.

A6. Case series.

A6. Molecular – Descriptive studies without validation or control group.

A7. Case report.

A7. Study in animal models and other in vitro studies.

A8. Experts’ consensus and opinion.

B. Research ethics:

B1. Approval by Ethics Committee or registration in PROSPERO;

B1. No need for a Research Ethics Committee according to resolution 466;

B2. No description or evaluation by Ethics Committee.

C. Study Design/Presentation

C1. Adequate description of the study with clear and reproducible methodology, consistent results and adequate conclusion, compatible with data presented.

C2. Adequate description with clear and reproducible methodology, consistent results, but inadequate conclusion.

C3. Adequate description of the study with clear and reproducible methodology, but with inconsistent results and inadequate conclusion.

C4. Adequate description of the study, but with weak/unclear methodology. Inconsistent results and inadequate (incompatible) conclusion.

C5. Inadequate description of the study. Severe flaws in the introduction, methodology, results, and conclusions.

C6. Not applicable. Methodology and / or results not described.

D. Originality

D1. Unpublished – new interpretation of the concept.

D2. Ratifies known concept, but of optional use.

D3. Ratifies classical concept of daily use.

E. Clinical/Social Relevance

E1. In the study subgroup, in clinical and/or social practice;

E2. In the study subgroup;

E3. No clinical applicability or does not fit.